These findings suggest that the neuroprotective effects of edaravone encompass its inhibition of TDP-43 misfolding and its enhancement of pathological TDP-43 clearance in TDP-43 proteinopathies, evidencing the broad applicability of edaravone (Soejima-Kusunoki et al., 2022). Here, TARDBP is linked to proteostasis deficiencies.